Médico Adjunto, Servicio de Hematología, Hospital Universitario de Salamanca
Verified email at
Cited by
Cited by
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes
S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ...
haematologica 93 (9), 1301-1309, 2008
Luspatercept in patients with lower-risk myelodysplastic syndromes
P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...
New England Journal of Medicine 382 (2), 140-151, 2020
Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification
S Carrancio, N López-Holgado, FM Sánchez-Guijo, E Villarón, V Barbado, ...
Experimental hematology 36 (8), 1014-1021, 2008
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial
JA Pérez-Simon, O López-Villar, EJ Andreu, J Rifón, S Muntion, ...
haematologica 96 (7), 1072, 2011
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome
O Lopez-Villar, JL Garcia, FM Sanchez-Guijo, C Robledo, EM Villarón, ...
Leukemia 23 (4), 664-672, 2009
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation
JA Pérez‐Simón, M Díez‐Campelo, R Martino, S Brunet, Á Urbano, ...
British journal of haematology 130 (3), 394-403, 2005
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation
JA Perez-Simon, D Caballero, M Diez-Campelo, R Lopez-Perez, ...
Leukemia 16 (8), 1423-1431, 2002
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
JA Pérez-Simón, M Díez-Campelo, R Martino, A Sureda, D Caballero, ...
Blood 102 (3), 1108-1113, 2003
Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy
M Pérez‐Ilzarbe, M Díez‐Campelo, P Aranda, S Tabera, T Lopez, ...
Transfusion 49 (9), 1901-1910, 2009
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease
F Sánchez-Guijo, T Caballero-Velázquez, O López-Villar, A Redondo, ...
Biology of Blood and Marrow Transplantation 20 (10), 1580-1585, 2014
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena
EM Ocio, FM Sanchez‐Guijo, M Diez‐Campelo, C Castilla, OJ Blanco, ...
American journal of hematology 78 (4), 302-305, 2005
Response to lenalidomide in myelodysplastic syndromes with del (5q): influence of cytogenetics and mutations
M Mallo, M Del Rey, M Ibanez, MJ Calasanz, L Arenillas, MJ Larráyoz, ...
British journal of haematology 162 (1), 74-86, 2013
Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients
C Santamaría, S Muntión, B Rosón, B Blanco, O López-Villar, S Carrancio, ...
haematologica 97 (8), 1218, 2012
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of …
JA Pérez-Simón, C Encinas, F Silva, MJ Arcos, M Díez-Campelo, ...
Biology of Blood and Marrow Transplantation 14 (10), 1163-1171, 2008
Chronic graft-versus-host disease
JA Perez-Simon, I Sanchez-Abarca, M Diez-Campelo, D Caballero, ...
Drugs 66 (8), 1041-1057, 2006
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
B Blanco, JA Pérez-Simón, LI Sánchez-Abarca, T Caballero-Velazquez, ...
haematologica 94 (7), 975, 2009
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
S Park, JF Hamel, A Toma, C Kelaidi, S Thépot, MD Campelo, V Santini, ...
Journal of Clinical Oncology 35 (14), 1591-1597, 2017
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
ÁF Remacha, B Arrizabalaga, A Villegas, MS Durán, L Hermosín, ...
Annals of hematology 94 (5), 779-787, 2015
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura
JA Pérez-Simón, S Tabera, ME Sarasquete, M Díez-Campelo, ...
Cytotherapy 11 (6), 698-705, 2009
The Medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate …
P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...
Blood 132, 1, 2018
The system can't perform the operation now. Try again later.
Articles 1–20